基金
F Hoffmann-La Roche and Jazz Pharmaceuticals.
竞争利益冲突
All authors report medical writing support funded by F Hoffmann-La Roche. L-PA received grants or contracts from AstraZeneca, Bristol Myers Squibb, Merck Sharpe & Dohme, and Pfizer; reports consulting fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck, Mirati, Merck Sharpe & Dohme, Novartis, Pfizer, PharmaMar, Sanofi, Servier, and Takeda; and received honoraria from AstraZeneca, Janssen, Merck, and Mirati; and the laboratory and clinical research facility where he conducts research was funded by Fundación Cris, Instituto de Salud Carlos III (INGENIO-PMP21/00107, PMPTA22/00167, PI20/00870, AC20/0070), the Madrid Regional Government (iLung-P2022/BMD-7437), and the Asociación Española Contra el cancer (AECC; RETOS245794PAZA). HB received grants or contracts (to their institution) from Amgen, Bristol Myers Squibb, and Eli Lilly; received consulting or advisory fees from AbbVie, Amgen, AstraZeneca, Axiom, Bayer, BeiGene, BerGenBio, BioNTech, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, EMD-Serono, Guardant, Genentech, Genmab, Gilead, Grid Therapeutics, Iobiotech, iTEO, Janssen, Jazz Pharmaceuticals, Merck, Mirati, Natera, Novartis, Novocure, Oncocyte, Pfizer, PharmaMar, Puma, RAPT, Regeneron, Takeda, and Summit; received honoraria from Amgen, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Pfizer, and Regeneron; received support for attending meetings and/or travel from Amgen, Bristol Myers Squibb, Eli Lilly, EMD-Serono, Genentech, Jazz Pharmaceuticals, Merck, Mirati, and Regeneron; participated in a data safety monitoring board or advisory board for Incyte, Novartis, Takeda, University of Pennsylvania CAR T Program, and Springworks; held stock options from Inspirna, Nucleai, and Sonnetbio; and received medical writing services funded by Amgen, AstraZeneca, Bristol Myers Squibb, F Hoffmann-La Roche, Jazz Pharmaceuticals, Merck, and Mirati. SVL received grants or contracts (to their institution) from AbbVie, Alkermes, AstraZeneca, Bristol Myers Squibb, Cogent Biosciences, Duality, Elevation Oncology, Ellipses, Genentech, Gilead, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma, RAPT, Synthekine, and SystImmune; and consulting fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech/F Hoffmann-La Roche, Gilead, GlaxoSmithKline, Guardant Health, Johnson & Johnson, Jazz Pharmaceuticals, Merck, Merus, Mirati, Natera, Novartis, OSE Immunotherapeutics, Pfizer, RAPT, Regeneron, Revolution Medicines, Takeda, and Yuhan. SP received grants or contracts (to their institution) from Amgen, Arcus, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F Hoffmann-La Roche/Genentech, GlaxoSmithKline, iTeos, Mirati, MSD, PharmaMar, Pfizer, Promontory Therapeutics, and Seattle Genetics; received consulting fees from AbbVie, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F Hoffmann-La Roche/Genentech, Foundation Medicine, F-Star, Genmab, Genzyme, Gilead, GlaxoSmithKline, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Merck Serono, Merrimack, Mirati, MSD, Novartis, Novocure, Nuvation Bio, Nykode Therapeutics, Pfizer, Pharma Mar, Promontory Therapeutics, Qlucore, Regeneron, Sanofi, Seattle Genetics, Takeda, and Zymeworks; payment or honoraria (to their institution) from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Foundation Medicine, GlaxoSmithKline, Illumina, Ipsen, Merck Sharpe & Dohme, Mirati, Novartis, Pfizer, Sanofi, Seattle Genetics, and Takeda; received support for attending meetings and/or travel (to their institution) from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F Hoffmann-La Roche/Genentech, Merck Sharpe & Dohme, Novartis, Pfizer, and Takeda; and participated in a data safety monitoring board or advisory board for AbbVie, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F Hoffmann-La Roche/Genentech, Foundation Medicine, F-Star, Genmab, Genzyme, Gilead, GlaxoSmithKline, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Merck Serono, Merrimack, Mirati, MSD, Novartis, Novocure, Nuvation Bio, Nykode Therapeutics, PharmaMar, Promontory Therapeutics, Pfizer, Qlucore, Regeneron, Sanofi, Seattle Genetics, Takeda, and Zymeworks. RSH received consulting fees from Amgen, ArriVent, AstraZeneca, Bristol Myers Squibb, Candel Therapeutics, Catalym, Checkpoint Therapeutics, Cybrexa Therapeutics, Eli Lilly, EMD Serono, F Hoffmann-La Roche, Genentech, Gilead, I-Mab Biopharma, Immunocore, Janssen, Mediflix, Merck, NextCure, Novartis, Pfizer, Regeneron, and Sanofi; received support for attending meetings and/or travel from American Association for Cancer Research, International Association for the Study of Lung Cancer, Society for Immunotherapy of Cancer, Southwest Oncology Group, and Friends of Cancer Research; participated in a data safety monitoring board or advisory board for AstraZeneca, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, I-Mab Biopharma, Immune-Onc Therapeutics, Immunocore, and Novartis; held leadership roles for American Association for Cancer Research, International Association for the Study of Lung Cancer, Society for Immunotherapy of Cancer, Southwest Oncology Group, and Friends of Cancer Research; held stock or stock options in Bolt Biotherapeutics, Checkpoint Therapeutics, and Immunocore Holdings; and was a non-executive board member for Immunocore Holdings and Junshi Pharmaceuticals. KS received payment or honoraria from AstraZeneca, Bristol Myers Squibb, F Hoffmann-La Roche, Janssen, Medison, Merck, Merck Sharpe & Dohme, Pfizer, and Takeda; support for attending meetings and/or travel from AstraZeneca, Merck Sharpe & Dohme, and Takeda; and participated in a data safety monitoring board or advisory board for BeiGene and Medison. MM received payment or honoraria from Amgen, AstraZeneca, Beigene, Boehringer Ingelheim, F Hoffmann-La Roche, Johnson & Johnson, Helssin, Immedica, Merck Sharpe & Dohme, Pfizer, and Takeda; support for attending meetings and/or travel from AstraZeneca, F Hoffmann-La Roche, and Merck Sharpe & Dohme; and participated in a data safety monitoring board or advisory board for Bayer. MANS received consulting fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, F Hoffmann-La Roche, Gilead, Janssen, Merck Sharpe & Dohme, Novartis, Pfizer, and Takeda; received payment or honoraria from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, F Hoffmann-La Roche, Gilead, Janssen, Merck Sharpe & Dohme, Novartis, Pfizer, and Takeda; and received support for attending meetings and/or travel from Bayer, Bristol Myers Squibb, F Hoffmann-La Roche, Merck Sharpe & Dohme, Novartis, and Pfizer. GC received payment or honoraria from Amgen, AstraZeneca, F Hoffmann-La Roche, Merck Sharpe & Dohme, Pfizer, and Takeda; received support for attending meetings and/or travel from Merck Sharpe & Dohme, Pfizer, and Takeda; and participated in a data safety monitoring board or advisory board for AstraZeneca and Bristol Myers Squibb. RBC received an investigational grant from F Hoffmann-La Roche; received payment or honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, F Hoffmann-La Roche, Merck Sharpe & Dohme, Pfizer, and Takeda; and participated in a data safety monitoring board or advisory board for AstraZeneca, Bristol Myers Squibb, F Hoffmann-La Roche, and Takeda. KHL received research funding from Merck; and received consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Johnson & Johnson/Janssen, Merck, Merck Sharpe & Dohme, Pfizer, Takeda, and Yuhan. MLJ received grants or contracts (to their institution) from AbbVie, Adaptimmune, Amgen, Arcus, Array BioPharma, ArriVent, Artios, AstraZeneca, Bayer, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, City of Hope National Medical Center, Conjupro Biotherapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Eli Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, F Hoffmann-La Roche/Genentech, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Harpoon, Helsinn Healthcare, Hengrui Therapeutics, Hutchinson MediPharma, IDEAYA Biosciences, IGM Biosciences, Immuneering Corporation, Immunitas Therapeutics, Immunocore, Impact Therapeutics, Incyte, Janssen, Kartos Therapeutics, LockBody Therapeutics, Loxo Oncology, Memorial Sloan-Kettering, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, NextPoint Therapeutics, Novartis, Numab Therapeutics, Nuvalent, OncoC4, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Theraeputics, Sanofi, Seven and Eight Biopharmaceuticals/Birdie Pharmaceuticals, Shattuck Labs, Silicon Therapeutics, Summit Therapeutics, Syndax Pharmaceuticals, Systimmune, Taiho Oncology, Takeda, TCR2 Therapeutics, Tempest Therapeutics, TheRas, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, Vividion, Vyriad, and Y-mAbs Therapeutics; and received consulting fees from AbbVie, Alentis Therapeutics, Amgen, Arcus Biosciences, AstraZeneca, Biohaven Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, D3 Bio, Daiichi Sankyo, Eli Lilly, Fate Therapeutics, F Hoffmann-La Roche/Genentech, Gilead, GlaxoSmithKline, Gritstone Oncology, Hookipa Biotech, Immunocore, Janssen, Jazz Pharmaceuticals, Merck, Mirati Therapeutics, ModeX Therapeutics, Normunity, Novartis, Novocure, Pfizer, Regeneron Pharmaceuticals, Revolution Medicines, Sanofi-Aventis, Seattle Genetics, Synthekine, Takeda, and Zai Laboratory. NK held stock or stock options in F Hoffmann-La Roche. CG received payment or honoraria from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, F Hoffmann-La Roche, Merck Sharpe & Dohme, Novartis, Novocure, PharmaMar, and Takeda. SB received grants or contracts (to self or their institution) from Amgen, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Eisai, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck Sharpe & Dohme, Novartis, Regeneron, and ZymeWorks; received consulting fees from AstraZeneca, Bristol Myers Squibb, F Hoffmann-La Roche, Janssen, and Merck Sharpe & Dohme; and received support for attending meetings and/or travel from Bristol Myers Squibb, Eli Lilly, Galenica, and Merck Sharpe & Dohme. JSA received payment or honoraria from Amgen Korea, AstraZeneca Korea, Bayer Korea, BC World, Boehringer Ingelheim, Boryung, Daiichi Sankyo Korea, Eli Lilly Korea, F Hoffmann-La Roche Korea, Kyowa Kirin, LG Chem, Menarini Korea, Nokwon Medical, Novartis Korea, Pfizer, Samyang, Takeda, and Yuhan; and participated in a data safety monitoring board or advisory board for Daiichi Sankyo Korea, F Hoffmann-La Roche, Guardant, Immuneoncia, Pfizer, Pharmbio, Therapex Korea, and Yuhan. RC received grants or contracts (to institution) from AstraZeneca, ArriVent, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck Sharpe & Dohme, OSE Immunotherapeutics, PharmaMar, and Taiho; received consulting fees from ArriVent, AstraZeneca, BioNTech, Bristol Myers Squibb, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck Sharpe & Dohme, Pfizer, PharmaMar, and Takeda; received payment or honoraria from AstraZeneca, BeiGene, GlaxoSmithKline, Janssen, Regeneron, and Takeda; received support for attending meetings and/or travel from Janssen and Takeda; participated in a data safety monitoring board or advisory board for ArriVent, AstraZeneca, Janssen, and PharmaMar; held a leadership or fiduciary role in the European Society for Medical Oncology Educational Publication Working Group and The European Organisation for Research and Treatment of Cancer Lung Group; and held stock or stock options in Supportive Care UK and Leaders in Oncology Care at the Christie Private Care. T-YY received payment or honoraria from AstraZeneca, Daiichi Sankyo, F Hoffmann-La Roche, Janssen, Merck Sharpe & Dohme, and Pfizer; and received support for attending meetings and/or travel from AstraZeneca, Daiichi Sankyo, F Hoffmann-La Roche, Janssen, Merck Sharpe & Dohme, and Pfizer. YK received consulting fees from F Hoffmann-La Roche, Novartis, and Pfizer; received payment or honoraria from AstraZeneca, Daiichi Sankyo, F Hoffmann-La Roche, Merck Sharpe & Dohme, Novartis, and Pfizer; and received support for attending meetings and/or travel from Amgen, AstraZeneca, F Hoffmann-La Roche, Gilead, and Novartis. MB, VC, VG, and Y-CL are employed by F Hoffmann-La Roche; hold stock or stock options in F Hoffmann-La Roche; and received support for attending meetings and/or travel from F Hoffmann-La Roche. DC is employed by Jazz Pharmaceuticals; holds stock or stock options in Jazz Pharmaceuticals; and received support for attending meetings and/or travel from Jazz Pharmaceuticals. KB, GC, and RI are employed by Jazz Pharmaceuticals; and hold stock or stock options in Jazz Pharmaceuticals. MR received consulting fees from Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Eli Lilly, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck, Mirati, Merck Sharpe & Dohme, Novartis, Pfizer, Regeneron, and Sanofi; received payment or honoraria from Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Eli Lilly, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck, Mirati, Merck Sharpe & Dohme, Novartis, Pfizer, Regeneron, and Sanofi; received support for attending meetings and/or travel from Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Eli Lilly, F Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck, Mirati, Merck Sharpe & Dohme, Novartis, Pfizer, Regeneron, and Sanofi; and participated in a data safety monitoring board or advisory board for Daiichi Sankyo and Sanofi. TC declares no competing interests.
